Sedelle Henderson-Bamidele, NP
Nurse Practitioner · Newark, DENPI 1407395759
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 60.3% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $3,623 and has fallen 69.7% since, to $1,099 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $126.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$8K
- AstraZeneca$913
- Akebia Therapeutics Inc$457
- Ardelyx, Inc.$344
- Gilead$327
- Novo Nordisk$243
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$7,00054%
- Travel & lodging$1651%
- Food & beverage$5,68244%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 28 | $7,751 |
| AstraZeneca | 16 | $913 |
| Akebia Therapeutics Inc | 7 | $457 |
| Ardelyx, Inc. | 6 | $344 |
| Gilead | 3 | $327 |
| Novo Nordisk | 3 | $243 |
| Boehringer Ingelheim | 3 | $241 |
| AbbVie | 2 | $241 |
| Vifor Pharma, Inc. | 5 | $219 |
| GSK | 3 | $211 |
| Amgen(2 entities) | 4 | $179 |
| Otsuka America Pharmaceutical, Inc. | 2 | $160 |
| Sun Pharmaceutical Industries Inc. | 1 | $142 |
| Regeneron | 1 | $117 |
| Dexcom, Inc. | 1 | $114 |
| Scynexis, Inc. | 1 | $113 |
| Neurocrine Biosciences, Inc. | 2 | $106 |
| Boston Scientific | 1 | $101 |
| Lilly USA, LLC | 1 | $100 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Cipher Pharmaceuticals US LLC | 1 | $99 |
| Sage Therapeutics, LLC | 1 | $98 |
| Mylan Specialty L.p. | 1 | $90 |
| Sumitomo Pharma America, Inc. | 1 | $87 |
| Inspire Medical Systems, Inc. | 1 | $85 |
| Acadia Pharmaceuticals Inc | 2 | $75 |
| Neurelis, Inc. | 1 | $59 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Bayer | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Velphoro$7,108
- Vafseo$351
- LOKELMA$253
- XPHOZAH 30 MG$232
- DRIZALMA SPRINKLE$142
- Ozempic$125
- FASENRA$125
- Veklury$125
- JARDIANCE$120
- ACTIMMUNE$120
- QULIPTA$116
- DEXCOM G6 TRANSMITTER$114
- Watchman$101
- MOUNJARO$100
How this compares
$12,860 in reported general payments places this provider in the 95th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 72 | $228,538 |
| XphozahTenapanor Hcl | 12 | $35,632 |
| AuryxiaFerric Citrate | 25 | $34,721 |
| Lanthanum Carbonate | 12 | $32,635 |
| EliquisApixaban | 13 | $12,401 |
| Sevelamer Carbonate | 36 | $11,735 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $10,605 |
| Midodrine Hcl | 17 | $1,379 |
| Calcium Acetate | 15 | $1,331 |
| Hydralazine Hcl | 13 | $366 |
| Gabapentin | 18 | $211 |
| Atorvastatin Calcium | 28 | $168 |
| Doxazosin Mesylate | 13 | $128 |
| Furosemide | 24 | $100 |
| Losartan Potassium | 17 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $7,751 | $228,53872 claims |
| Akebia Therapeutics IncAuryxia | $457 | $34,72125 claims |
| AstraZenecaLokelma | $913 | $10,60516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Newark
- Funmilola OlaoyeNewark$7K
- Lyron DeputyNewark$6K
- Mark LandisNewark$5K
- Noreen Murphy BowensNewark$4K
- Mary ZimnyNewark$4K
- Amanda WardwellNewark$4K
- Heather DennisNewark$4K
- Anesha VictorNewark$3K
- Lori GrantNewark$3K
- Alexandra QuinnNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.